Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,036,304
  • Shares Outstanding, K 2,041,735
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,645 M
  • EBITDA $ 16,656 M
  • 60-Month Beta 0.27
  • Price/Sales 2.57
  • Price/Cash Flow 7.46
  • Price/Book 6.67

Options Overview Details

View History
  • Implied Volatility 31.24% (+1.69%)
  • Historical Volatility 24.12%
  • IV Percentile 59%
  • IV Rank 30.45%
  • IV High 55.70% on 04/10/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 8) 1.67 (2.82%)
  • Put/Call Vol Ratio 1.28
  • Today's Volume 16,323
  • Volume Avg (30-Day) 21,819
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 518,679
  • Open Int (30-Day) 577,406
  • Expected Range 57.62 to 60.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.46
  • Number of Estimates 10
  • High Estimate $1.59
  • Low Estimate $1.39
  • Prior Year $1.80
  • Growth Rate Est. (year over year) -18.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.45 +4.89%
on 03/24/26
62.58 -5.39%
on 03/04/26
-3.13 (-5.02%)
since 03/02/26
3-Month
52.06 +13.73%
on 01/05/26
62.89 -5.85%
on 03/02/26
+5.75 (+10.76%)
since 01/02/26
52-Week
42.52 +39.25%
on 10/29/25
62.89 -5.85%
on 03/02/26
-0.39 (-0.65%)
since 04/02/25

Most Recent Stories

More News
3 Value Stocks Walking a Fine Line

3 Value Stocks Walking a Fine Line

APAM : 36.28 (-0.77%)
UTZ : 7.68 (-0.52%)
BMY : 59.33 (-2.90%)
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care

BMY : 59.33 (-2.90%)
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

TLYS : 4.18 (-0.48%)
UTHR : 555.28 (-2.63%)
BMY : 59.33 (-2.90%)
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 ...

BMY : 59.33 (-2.90%)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies

BMY : 59.33 (-2.90%)
Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

LMB : 80.63 (+0.54%)
PAYO : 4.89 (+1.24%)
MU : 364.40 (-0.94%)
HOOD : 69.18 (-1.33%)
BMY : 59.33 (-2.90%)
Why Bristol-Myers Squibb (BMY) Stock Is Up Today

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

BMY : 59.33 (-2.90%)
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Positive Phase 3 results of SCOUT-HCM trial highlight potential of Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescents with symptomatic obstructive hypertrophic...

BMY : 59.33 (-2.90%)
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric...

BMY : 59.33 (-2.90%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 66.24 (+1.16%)
AAPL : 255.42 (-0.08%)
AVGO : 312.85 (-0.20%)
CVX : 199.03 (+0.82%)
VZ : 49.44 (+0.10%)
$SPX : 6,559.73 (-0.24%)
JPM : 295.04 (-0.12%)
JNJ : 244.00 (-0.05%)
SCHD : 30.48 (-0.10%)
ABBV : 208.28 (-3.12%)
BMY : 59.33 (-2.90%)
MSFT : 371.71 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 63.70
2nd Resistance Point 62.96
1st Resistance Point 62.35
Last Price 59.33
1st Support Level 60.99
2nd Support Level 60.25
3rd Support Level 59.64

See More

52-Week High 62.89
Last Price 59.33
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.